IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation
- PMID: 9700502
- DOI: 10.1111/j.1600-065x.1998.tb01188.x
IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation
Abstract
The Fc region of human IgG expresses interaction sites for many effector ligands. In this review the topographical distributions of ten of these sites are discussed in relation to functional requirement. It is apparent that interaction sites localised to the inter-CH2-CH3 domain region of the Fc allow for functional divalency, whereas sites localised to the hinge proximal region of the CH2 domain are functionally monovalent, with expression of the latter sites being particularly dependent on glycosylation. All x-ray crystal structures for Fc and Fc-ligand complexes report that the protein structure of the hinge proximal region of the CH2 domain is "disordered", suggesting "internal mobility". We propose a model in which such "internal mobility" results in the generation of a dynamic equilibrium between multiple conformers, certain of which express interaction sites specific to individual ligands. The emerging understanding of the influence of oligosaccharide/protein interactions on protein conformation and biological function of IgG antibodies suggests a potential to generate novel glycoforms of antibody molecules having unique profiles of effector functions.
Similar articles
-
Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity.J Mol Biol. 2003 Jan 31;325(5):979-89. doi: 10.1016/s0022-2836(02)01250-0. J Mol Biol. 2003. PMID: 12527303
-
Glycobiology: 'the function of sugar in the IgG molecule'.J Anat. 1995 Oct;187 ( Pt 2)(Pt 2):279-92. J Anat. 1995. PMID: 7591992 Free PMC article.
-
Glycoform-dependent conformational alteration of the Fc region of human immunoglobulin G1 as revealed by NMR spectroscopy.Biochim Biophys Acta. 2006 Apr;1760(4):693-700. doi: 10.1016/j.bbagen.2005.10.002. Epub 2005 Oct 26. Biochim Biophys Acta. 2006. PMID: 16343775
-
Interaction sites on human IgG-Fc for FcgammaR: current models.Immunol Lett. 2002 Jun 3;82(1-2):57-65. doi: 10.1016/s0165-2478(02)00019-6. Immunol Lett. 2002. PMID: 12008035 Review.
-
Isotype and glycoform selection for antibody therapeutics.Arch Biochem Biophys. 2012 Oct 15;526(2):159-66. doi: 10.1016/j.abb.2012.03.021. Epub 2012 Mar 23. Arch Biochem Biophys. 2012. PMID: 22465822 Review.
Cited by
-
Murlentamab, a Low Fucosylated Anti-Müllerian Hormone Type II Receptor (AMHRII) Antibody, Exhibits Anti-Tumor Activity through Tumor-Associated Macrophage Reprogrammation and T Cell Activation.Cancers (Basel). 2021 Apr 13;13(8):1845. doi: 10.3390/cancers13081845. Cancers (Basel). 2021. PMID: 33924378 Free PMC article.
-
Genetic and antigenic analysis of mink's immunoglobulin G Fc region.Cent Eur J Immunol. 2014;39(1):36-9. doi: 10.5114/ceji.2014.42120. Epub 2014 Apr 17. Cent Eur J Immunol. 2014. PMID: 26155097 Free PMC article.
-
Enzymatic deglycosylation converts pathogenic neuromyelitis optica anti-aquaporin-4 immunoglobulin G into therapeutic antibody.Ann Neurol. 2013 Jan;73(1):77-85. doi: 10.1002/ana.23741. Epub 2012 Oct 10. Ann Neurol. 2013. PMID: 23055279 Free PMC article.
-
The Fab portion of immunoglobulin G contributes to its binding to Fcγ receptor III.Sci Rep. 2019 Aug 16;9(1):11957. doi: 10.1038/s41598-019-48323-w. Sci Rep. 2019. PMID: 31420591 Free PMC article.
-
Post-translational modifications differentially affect IgG1 conformation and receptor binding.Mol Cell Proteomics. 2010 Aug;9(8):1716-28. doi: 10.1074/mcp.M900540-MCP200. Epub 2010 Jan 26. Mol Cell Proteomics. 2010. PMID: 20103567 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
